ArticleHepatology (Baltimore, Md.)2014
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach.
Article in Hepatology (Baltimore, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma.Cancer medicine · 2019Pooled it
- Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Article
- Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?Journal of hepatology · 2023Review
- Early cost-utility analysis of hepatitis C virus testing for emergency department attendees in France.PLOS global public health · 2023Article
- Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.Journal of hepatology · 2022Article
- Early detection of hepatocellular carcinoma: roadmap for improvement.Expert review of anticancer therapy · 2022Article
- Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Review
- Is hepatocellular carcinoma surveillance in high-risk populations effective?Hepatic oncology · 2020Review
- Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma.Cellular and molecular life sciences : CMLS · 2019Review
- Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk?Digestive diseases and sciences · 2019Review
- Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2019Article
- Status of, and strategies for improving, adherence to HCC screening and surveillance.Journal of hepatocellular carcinoma · 2019Review
- A Retrospective Cohort Study of Nasopharyngeal Carcinoma Screening and Hepatocellular Carcinoma Screening in Zhongshang City.Journal of Cancer · 2019Article
- Sperm-Associated Antigen 5 Expression Is Increased in Hepatocellular Carcinoma and Indicates Poor Prognosis.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis.Hepatology (Baltimore, Md.) · 2018Article
- Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Journal of hepatology · 2018Review
- Detection of hepatocellular carcinoma by tissue resonance interaction method (TRIM).Przeglad gastroenterologiczny · 2018Article
- Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?Current hepatology reports · 2017Article
- Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.British journal of cancer · 2017Article
- No Need of Immediate Treatment for Hypovascular Tumors Associated with Hepatocellular Carcinoma.World journal of surgery · 2016Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledBecause of the ongoing debate on the benefit of ultrasound (US) screening for hepatocellular carcinoma (HCC), we assessed the impact of screening on hepatitis C virus (HCV)-related compensated cirrhosis patients aware of their HCV status. A Markov model simulated progression from HCC diagnosis to death in 700 patients with HCV-related compensated cirrhosis aware of their HCV status to estimate life expectancy (LE) and cumulative death at 5 years. Five scenarios were compared: S1, no screening; S2, screening by currently existing practices (57% access and effectiveness leading to the diagnosis of 42% at Barcelona Clinic Liver Cancer stage [BCLC-0/A]); S3, S2 with increased access (97%); S4, S2 with an efficacy of screening close to that achieved in a randomized controlled trial leading to the diagnosis of 87% of patients at stage BCLC-0/A; S5, S3+S4. The analysis was corrected for lead-time bias. Currently existing practices of HCC screening increased LE by 11 months and reduced HCC mortality at 5 years by 6% compared to no screening (P = 0.0013). Compared to current screening practices, we found that: 1) increasing the rate of access to screening would increase LE by 7 months and reduce HCC mortality at 5 years by 5% (P = 0.045); 2) optimal screening would increase LE by 14 months and reduce HCC mortality at 5 years by 9% (P = 0.0002); 3) the combination of an increased rate of access and optimal effectiveness of HCC screening would increase LE by 31 months and decrease HCC mortality at 5 years by 20% (P < 0.0001).
conclusionThe present study shows that US screening for HCC in patients with compensated HCV-related cirrhosis aware of their HCV status improves survival and emphasizes the crucial role of screening effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.